Rexahn Pharmaceuticals, Inc. RNN, a clinical stage
biopharmaceutical company developing potential best-in-class oncology
therapies, today announced that it has significantly expanded its intellectual
property around a series of novel anti-tumor quinazoline compounds. Rexahn has
been issued patent No. 8,404,698 from the U.S. Patent and Trademark Office,
covering these novel quinazoline compounds, their pharmaceutical composition,
and method for producing an anti-tumor effect.
The series of compounds included in this issued patent are inhibitors of an
epidermal growth factor receptor (EGFR). EGFRs are cell surface receptors and
mutations in these receptors can cause accelerated cell growth leading to lung
and colon cancer. Mutated EGFRs account for approximately 30% of epithelial
cancers. In preclinical trials, Rexahn's patented compounds have demonstrated
oral bioavailability and anti-tumor activity in an animal model that did not
respond well to Taxol, an oncology drug used to treat lung, breast and ovarian
cancer.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in